Figure 2 shows the flow of patients through the study. The baseline characteristics of the 457 participants who provided information on their preference are shown in Table 1. 19% would be recommended SGLT2-inhibitors in current international guidance from the American and European diabetes associations, which propose preferential choice of SGLT2 inhibitors in cardiovascular and renal disease (n=68 with atherosclerotic cardiovascular disease, n=22 with microalbuminuria/proteinuria, n=5 with both)4. Here, SLC5A2 is linked to diabetes mellitus.